<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02911337</url>
  </required_header>
  <id_info>
    <org_study_id>WTLSSCHF</org_study_id>
    <nct_id>NCT02911337</nct_id>
  </id_info>
  <brief_title>Weight Loss as Therapy for Heart Failure With Preserved Ejection Fraction</brief_title>
  <acronym>WTLSSCHF</acronym>
  <official_title>Weight Loss as Therapy for Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the efficacy of an intensive, supervised, lifestyle&#xD;
      modification program on symptoms and signs of heart failure as well as laboratory and&#xD;
      echocardiographic measures of cardiac structure and function. This will be a 6 month trial in&#xD;
      50 patients with a clinical diagnosis of heart failure with preserved ejection fraction&#xD;
      (HFpEF). Patients will be enrolled in the Medical University of South Carolina weight&#xD;
      management 15 week lifestyle change program which will involve weekly visits that rotate&#xD;
      among the clinical specialities (dietary, exercise and behavioral) and scheduled visits with&#xD;
      the research Registered Nurse. Each patients baseline data will be used as the control and&#xD;
      compared with the same measurements at the 6 month end point.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">December 28, 2018</completion_date>
  <primary_completion_date type="Actual">December 28, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 6 minute hall walk test from baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Exercise capacity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in symptoms measured with the Minnesota Living With Heart Failure(MLWHF) scores</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of life assessment specific for congestive heart failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular mass</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in left ventricular mass will be measured by transthoracic echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Natriuretic Peptide</measure>
    <time_frame>6 months</time_frame>
    <description>Brain natriuretic peptide will be measured in serum using standard commercial assay</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Left Atrial Volume</measure>
    <time_frame>6 months</time_frame>
    <description>Left atrial volume will be measured by transthoracic echocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Early mitral inflow velocity/mitral annular velocity (E/e')</measure>
    <time_frame>6 months</time_frame>
    <description>E/e' will be measured by transthoracic echocardiography</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Heart Failure, Diastolic</condition>
  <condition>Weight Loss</condition>
  <arm_group>
    <arm_group_label>Lifestyle modification</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lifestyle modification</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>lifestyle modification</intervention_name>
    <description>Subjects will be given meal replacements (shakes and bars) to be consumed twice per day for 8 weeks, and then once per day for an additional 3 weeks, and then transitioned to a structured diet.</description>
    <arm_group_label>Lifestyle modification</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI &gt; 30&#xD;
&#xD;
          -  Able to perform 6 minute hall walk test&#xD;
&#xD;
          -  Left Ventricular ejection fraction &gt;45%&#xD;
&#xD;
          -  Diagnosis of heart failure with preserved ejection fraction (HFpEF) ; confirmation of&#xD;
             HFpEF based on 1 major or 3 minor criteria listed below.&#xD;
&#xD;
        Major:&#xD;
&#xD;
          1. Elevated BNP &gt;200&#xD;
&#xD;
          2. cardiogenic pulmonary edema&#xD;
&#xD;
          3. Pulmonary capillary wedge pressure at rest &gt;15 mmhg or with exercise &gt;25 mmhg using&#xD;
             invasive right heart pressure measurement&#xD;
&#xD;
        Minor:&#xD;
&#xD;
          1. Left atrial enlargement (volume &gt;68 ml)&#xD;
&#xD;
          2. increased left ventricular wall thickness (&gt;1.1cm) by echocardiography&#xD;
&#xD;
          3. E/e' &gt;15&#xD;
&#xD;
          4. intermediate level of BNP, 60-199&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  uncontrolled blood pressure&#xD;
&#xD;
          -  severe chronic obstructive pulmonary disease (oxygen or steroid dependent)&#xD;
&#xD;
          -  recurrent major depression. presence or history of suicide behavior, and current&#xD;
             substantial depressive symptoms. Antidepressant drugs are allowed if the dose has been&#xD;
             stable for 3 months&#xD;
&#xD;
          -  other major psychiatric illness (schizophrenia, bipolar, dementia)&#xD;
&#xD;
          -  significant hepatic dysfunction&#xD;
&#xD;
          -  untreated hypothyroidism or hyperthyroidism&#xD;
&#xD;
          -  history of drug or alcohol abuse or dependency within the past 12 months&#xD;
&#xD;
          -  acute coronary syndrome without revascularization in the past 12 months&#xD;
&#xD;
          -  acute coronary syndrome with revascularization in the past 6 months&#xD;
&#xD;
          -  Cerebrovascular accident or transient ischemic attack in the past 6 months&#xD;
&#xD;
          -  cancer or terminal illness with life expectancy &lt; 3 years&#xD;
&#xD;
          -  history of medical noncompliance&#xD;
&#xD;
          -  significant anemia (hgb &lt;9)&#xD;
&#xD;
          -  life threatening or uncontrolled arrhythmia&#xD;
&#xD;
          -  hemodynamically relevant valvular heart disease&#xD;
&#xD;
          -  infiltrative heart disease including cardiac amyloidosis, sarcoidosis, Fabry's disease&#xD;
&#xD;
          -  genetic hypertrophic cardiomyopathy&#xD;
&#xD;
          -  significant pericardial disease&#xD;
&#xD;
          -  clinically relevant neuromuscular disease&#xD;
&#xD;
          -  pregnant or may become pregnant in the next 6 months&#xD;
&#xD;
          -  prior major organ transplant or intent to transplant ( on the transplant list)&#xD;
&#xD;
          -  pacemaker dependant&#xD;
&#xD;
          -  clinically significant congenital heart disease that may be cause of symptoms&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MUSC Gazes Research Institue</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>July 23, 2015</study_first_submitted>
  <study_first_submitted_qc>September 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2016</study_first_posted>
  <last_update_submitted>January 2, 2019</last_update_submitted>
  <last_update_submitted_qc>January 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Sheldon Litwin</investigator_full_name>
    <investigator_title>Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

